About this theme
This research theme addresses two key components of health protection evaluation: identifying the impact of interventions on incidence, prevalence and prevention of infection; and determining the intervention components or programmes which represent cost-effective control of infection.
Viral hepatitis - intervention development and prevention
Our research focuses on the development and evaluation of prevention and treatment interventions to reduce the transmission and health consequences of the Hepatitis B (HBV) and Hepatitis C (HCV) viruses. We use modelling and health economic models to evaluate the impact and cost-effectiveness of new, existing and emerging interventions based on existing evidence and specific cost and outcome data collected for key interventions from a range of sites in UK and Globally.
Designing optimal control programmes for meningococcal disease
We use mathematical and health economic models to understand how best to prevent the transmission and health consequences of meningococcal disease, which is a leading cause of death in young children in the UK and can leave survivors with disabling complications.
Mathematical modelling to support tuberculosis control and interventions in England
Controlling TB is one of Public Health England's top priorities. We are assessing how multi-faceted tuberculosis (TB) control measures, including swift diagnosis and contact tracing, can be improved.
We also provide expertise in modelling and economic evaluation for responsive research projects.
Our work aims to understand how best to use new technologies, such as rapid diagnostic tests or vaccines, to control sexually transmitted infections to obtain value for money.
A comparison of the cost of different methods of re-testing chlamydia positive individuals in England
Analysis of the potential for point-of-care tests to enable individualised treatment of infections caused by antimicrobial resistant and susceptible strains of Neisseria gonorrhoeae: a modelling study
Cost-effectiveness of different interventions to improve the testing and linkage to care for people with Hepatitis C
Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling
- Peter Vickerman, Professor (University of Bristol)
- Mary Ramsay, Dr (Public Health England)
- Ellen Brooks-Pollock, Dr (University of Bristol)
- Hannah Christensen, Dr (University of Bristol)
- Caroline Coope, Dr (Public Health England)
- Hannah Fraser, Dr (University of Bristol)
- William Hollingworth, Professor (University of Bristol)
- Vivian Hope, Dr (Public Health England)
- Aaron Lim, Dr (University of Bristol)
- Katharine Looker, Dr (University of Bristol)
- Jack Stone, Mr (University of Bristol)
- Adam Trickey, Mr (University of Bristol)
- Katy Turner, Dr (University of Bristol)
- Josephine Walker, Dr (University of Bristol)
- Zoe Ward, Dr (University of Bristol)
Bristol Infectious Disease Dynamics Group
Find out more about the University of Bristol Infectious Disease Dynamics research group.